Product image of Montelukast Almus (Montelukast) supplied by GNH India

Montelukast Almus

Active Ingredient:
Montelukast
Origin:
EU

Montelukast Almus (Montelukast)

Montelukast, the active ingredient in Montelukast Almus, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma and allergic rhinitis in both adult and pediatric patients.
GNH India supplies Montelukast Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Almus Farmaceutica S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Montelukast acts on the leukotriene pathway to control chronic respiratory conditions.

  • Asthma (maintenance therapy): improves long‑term control of symptoms and reduces exacerbations.
  • Allergic rhinitis (seasonal or perennial): relieves nasal congestion, sneezing and itching.
  • Exercise‑induced bronchoconstriction: helps prevent airway narrowing during physical activity.

How It Works

  • Montelukast selectively blocks the cysteinyl leukotriene (CysLT1) receptor, preventing leukotrienes D4, E4 and related mediators from binding. This inhibition reduces bronchial smooth‑muscle contraction, vascular permeability, and inflammatory cell recruitment in the airways, thereby improving respiratory function and decreasing allergic inflammation.

Side Effects

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Headache: mild to moderate pain often reported.
  • Abdominal pain: discomfort in the stomach area.
  • Cough: occasional irritation of the throat.
  • Dyspepsia: indigestion or upset stomach.
  • Fatigue: feeling unusually tired.
  • Nausea: sensation of needing to vomit.

Serious or Rare Side Effects

  • Allergic reactions: rash, angioedema, or anaphylaxis.
  • Neuropsychiatric events: depression, mood changes, or suicidal thoughts.
  • Hepatic enzyme elevation: abnormal liver function tests.
  • Neutropenia: reduced white blood cell count.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Before initiating Montelukast, consider the following safety measures.

  • Assess asthma control: ensure patient is stable on current therapy.
  • Monitor neuropsychiatric symptoms: watch for mood changes or depression.
  • Use caution in hepatic impairment: adjust use if liver disease is present.
  • Avoid in known hypersensitivity: discontinue if allergic reaction occurs.
  • Not for acute asthma attacks: do not replace rescue inhalers.
  • Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Montelukast may interact with other medicines; review patient medication lists.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce Montelukast exposure.
  • Concurrent leukotriene modifiers (e.g., zafirlukast, zileuton): increase risk of adverse effects.

Moderate Interactions (Monitor Closely)

  • Antidepressants (e.g., fluoxetine, sertraline): may heighten neuropsychiatric risk.
  • Theophylline: additive bronchodilator effect may require dose adjustment.
  • Antihistamines: potential for increased sedation.
  • Warfarin: possible alteration of anticoagulant effect, monitor INR.

Frequently Asked Questions

Montelukast Almus is prescribed for the long‑term management of asthma, for relief of symptoms associated with allergic rhinitis, and to prevent exercise‑induced bronchoconstriction. It works by reducing airway inflammation and narrowing, helping patients achieve better respiratory control.

Montelukast blocks the cysteinyl leukotriene (CysLT1) receptor, preventing leukotrienes D4, E4 and related compounds from triggering inflammation, bronchial smooth‑muscle contraction, and mucus production. This receptor antagonism reduces airway swelling and improves breathing.

The specific dose of Montelukast Almus is determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Healthcare providers set the appropriate regimen and adjust it as needed.

Safety data for Montelukast Almus in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is especially useful for patients who prefer oral therapy or have difficulty using inhalers, though it is typically used as add‑on therapy rather than a sole rescue medication.

Montelukast Almus should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and extreme heat to maintain its stability and potency.

Montelukast Almus is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise instructed by a healthcare professional.

Serious risks include rare allergic reactions such as angioedema or anaphylaxis, and neuropsychiatric events like depression, mood changes, or suicidal thoughts. Patients should seek immediate medical attention if they experience any severe rash, breathing difficulty, or significant changes in mood.

Montelukast Almus should be avoided in individuals with known hypersensitivity to Montelukast or any component of the formulation. It is also not suitable for treating acute asthma attacks, and patients with uncontrolled severe liver disease should use it only under close medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Montelukast

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT